COVID-19 vaccine effectiveness on variants of concern
(Randomized evidence)

If you want to see all variants, please click here

Beta

Forest plots
(last update: 2021-10-28)

Description of primary studies

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
Beta
NCT04444674
AstraZeneca + University of Oxford
Madhi S, N Engl J Med, 2021
COV005

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in 7 centres in South Africa N=2026 Variant beta:

Some concerns
Details

Full description

Beta
Gamma
Delta
NCT04611243
Sinovac Research and Development Co., Ltd; and Pfizer/BioNTech + Fosun Pharma
Mok C K P, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac/Boost

CoronaVac/Boost BNT162b2

RCT
*
Adults that had received two doses of CoronaVac but had low immune response against SARS-CoV-2 at two centres in Hong Kong, China N=80
Some concerns
Details

Full description

Beta
Gamma
NCT04764422
The Government Pharmaceutical Organization (GPO); PATH; Dynavax
Pitisuttithum P, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

NDV-HXP-S 1mcg

NDV-HXP-S 1mcg + CpG1018

NDV-HXP-S 3mcg

NDV-HXP-S 3mcg + CpG1018

NDV-HXP-S 10mcg

NDV-HXP-S 1mcg

Placebo

RCT
Phase 1
Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand N=210
Some concerns
Details

Full description

Beta
NCT04505722
Janssen Pharmaceutical Companies
Sadoff J(2), N Engl J Med, 2021
ENSEMBLE

Full text
Commentary
Non replicating viral vector

Ad26.COV2.S

Placebo

RCT
Phase 3
Adults >18 years of age at 213 centers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and USA N=44325 Variant beta:

Some concerns
Details

Full description

Beta
NCT04533399; PACTR202009726132275
Novavax
Shinde V, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 2
HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa N=4406 Variant beta:

Some concerns
Details

Full description

Beta
Delta
NCT04762680
Sanofi Pasteur + GlaxoSmithKline
Sridhar S, medrxiv, 2021

Full text
Commentary
Commentary
Protein subunit

CoV2 preS dTM 15µg

CoV2 preS dTM 10µg

CoV2 preS dTM 5µg

RCT
Phase 2
Adults with and without prior SARS-CoV-2 infection and risk factors for severe disease at 20 centers in the USA and Honduras N=722
Low
Details

Full description

Beta
NCT04368728
Pfizer/BioNTech+Fosun Pharma
Thomas S, N Engl J Med, 2021

Full text
Commentary
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2-3
Children (>=12Y yo), adolescentes and adults, with no history or SARS-CoV 2 infection at 152 sites in Argentina, Brazil, Germany, South Africa, Turkey and USA N=44165 Variant beta:

Some concerns
Details

Full description